208 results on '"Harrup, Rosemary"'
Search Results
2. Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future
3. Asciminib monotherapy as frontline treatment of chronic phase chronic myeloid leukemia: results from the ASCEND study
4. Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry)
5. Physical activity and glioma: a case–control study with follow-up for survival
6. Adult medulloblastoma in an Australian population
7. Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial.
8. CTNI-54. A COMBINED ANALYSIS OF TWO RANDOMISED STUDIES EXPLORING THE IMPACT OF EXTENDED POST-RADIATION TEMOZOLOMIDE ON SURVIVAL OUTCOMES IN NEWLY DIAGNOSED GLIOBLASTOMA
9. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
10. Patient and carer experiences of living with multiple myeloma and myelodysplastic syndrome.
11. Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study.
12. Chronic lymphocytic leukaemia Australasian consensus practice statement.
13. Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26
14. Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers
15. Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26.
16. Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML
17. Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma
18. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
19. Do Australian adolescentsʼ and young adultsʼ experiences of cancer care influence their quality of life?
20. Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single‐centre, retrospective review in the Australian setting
21. Additional file 1 of Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry)
22. Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study
23. Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)
24. RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL
25. Acute myeloid leukemia with diabetes insipidus and hypophyseal infiltration
26. Medical oncology group of Australia, MOGA
27. Treatment and Outcomes for Central Nervous System Tumors in Australian Adolescents and Young Adults: A Population-Based National Study
28. Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels
29. QOLP-23. PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE
30. Severe Infusion-Related Reaction to Liposomal Amphotericin B
31. Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study.
32. Exploring the impact and experience of fractional work in medicine: a qualitative study of medical oncologists in Australia
33. Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)
34. Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study
35. Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study
36. Asciminib monotherapy as frontline treatment of chronic phase chronic myeloid leukemia: results from the ASCEND study
37. Management of Sarcoma in Adolescents and Young Adults: An Australian Population-Based Study
38. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
39. Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study
40. Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status
41. Clinical trial participation by adolescents and young adults with cancer: A continued cause for concern?
42. The Australian Medical Oncologist Workforce Survey: The profile and challenges of medical oncology
43. Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying
44. Experiences of Care of Adolescents and Young Adults with Cancer in Australia
45. Factors influencing the provision of fertility counseling and impact on quality of life in adolescents and young adults with cancer
46. A mixed methods analysis of experiences and expectations among early-career medical oncologists in Australia
47. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
48. Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study
49. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
50. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.